Clinical trials: Plasma Cell Mediated
Multiple Myeloma
Autologous Memory-like NK Cell Therapy With BHV-1100 and Low Dose IL-2 in Multiple Myeloma Patients
This is an open-label single center Phase 1a/1b study with the primary objective of establishing the safety and exploring the efficacy of infusing the ex vivo combination product of BHV-1100 plus cytokine induced memory-like…
- Trial name
- NCT04634435
- Testing
- BHV-1100 plus cytokine induced memory-like (CIML) NK cells plus IVIG and low dose IL-2
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Biohaven Pharmaceuticals, Inc.
Multiple Myeloma
Study of Propranolol to Decrease Gene Expression of Stress-Mediated Beta-Adrenergic Pathways in HCT Recipients
This is a randomized controlled pilot study designed to evaluate whether the beta-adrenergic antagonist propranolol is effective in decreasing gene expression of stress-mediated beta-adrenergic pathways among a cohort of…
- Trial name
- NCT02420223
- Testing
- Propranolol
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Medical College of Wisconsin
Plasma Cell Mediated, Antibody Mediated
Compassionate Use of Vonsetamig
Provide Compassionate Use of Vonsetamig
- Trial name
- NCT07780110
- Testing
- Vonsetamig
- Sponsor
- Regeneron Pharmaceuticals
Multiple Myeloma, Chemotherapy-Induced Peripheral Neuropathy
Long Non-coding RNA (lncRNA) ZFAS1-Mediated Mechanism of Roasted Nux Vomica in Intervening Bortezomib-Induced Peripheral Neuropathy
This study aims to evaluate the efficacy and safety of Roasted Nux Vomica Capsules in the treatment of BIPN in patients with multiple myeloma.
- Trial name
- ZFAS1-BIPN (NCT07614243)
- Testing
- Roasted Nux Vomica Capsules
- Where
- China
- Volunteers
- 22 people
- Sponsor
- The First Affiliated Hospital of Zhejiang Chinese Medical University
Food Allergy
Short-Term Linvoseltamab Treatment on Top of Chronic Dupilumab Treatment for Adults With Severe Immunoglobulin E (IgE)-Mediated Food Allergy
This study is researching an experimental drug called linvoseltamab combined with another drug called dupilumab. The study is looking at patients who have severe IgE-mediated food allergy.
- Trial name
- NCT06369467
- Testing
- linvoseltamab, dupilumab
- Where
- 5 sites in United States
- Volunteers
- 6 people
- Sponsor
- Regeneron Pharmaceuticals
Multiple Myeloma, Myeloma
A Phase II Trial of Anti-KIR in Smoldering Multiple Myeloma
Background: Recent studies have shown that smoldering multiple myeloma has a high risk of progressing to multiple myeloma, an aggressive type of bone marrow cancer, within 5 years of diagnosis.
- Conditions
- Multiple Myeloma, Myeloma, Smoldering Multiple Myeloma
- Trial name
- NCT01248455
- Testing
- (Anti-KIR)
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- National Cancer Institute (NCI)
Multiple Myeloma
Simvastatin as Inhibitor of Cell Adhesion Mediated Drug Resistance in Patients With Refractory Multiple Myeloma.
In vitro statins, inhibitors of the HMG-CoA-reductase, have been shown to overcome cell adhesion mediated drug resistance at very low concentrations.
- Trial name
- NCT00399867
- Testing
- Simvastatin
- Volunteers
- 30 people
- Sponsor
- Ludwig-Maximilians - University of Munich
Oral Submucous Fibrosis
Alternating Triamcinolone and Platelet-Rich Plasma Therapy for Oral Submucous Fibrosis
Oral Submucous Fibrosis (OSF) is a chronic, progressive, potentially malignant disorder characterized by mucosal stiffness, trismus, and burning sensation.
- Trial name
- RegenOSF (NCT07277998)
- Testing
- Platelet-Rich Plasma (PRP) Injections, Triamcinolone Acetonide
- Where
- Pakistan
- Volunteers
- 40 people
- Sponsor
- Karachi Medical and Dental College
Relapsed and Refractory Multiple Myeloma
Mezigdomide Plus Ixazomib and Dexamethasone for Relapsed and Refractory Multiple Myeloma
Multiple myeloma (MM) is the second most common hematologic malignancy with an estimated annual incidence of nearly 35,000 cases.
- Trial name
- NCT06050512
- Testing
- Mezigdomide, Ixazomib, Dexamethasone
- Sponsor
- Kathleen Dorritie
IgM MGUS, Waldenstrom Macroglobulinemia
ACALA-R In Predominantly Demyelinating IgM Mediated Neuropathy
In this research study, is combining a new treatment acalabrutinib with a standard treatment, rituximab or other CD20 antibody, to determine whether this combination is safe and effective for participants with Immunoglobulin (Ig)…
- Conditions
- IgM MGUS, Waldenstrom Macroglobulinemia, Neuropathy;Peripheral
- Trial name
- NCT05065554
- Testing
- Acalabrutinib, Rituximab
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Shayna Sarosiek, MD
Cancer, Spinal Disease
Anderson Circulating Tumor Cell Burden (CTCB) Study
Phase 1 - Optimization Phase: Primary Objective: The primary objective of Phase 1 of this study is to determine the time point at which maximal Circulating Tumor Cell Burden (CTCB) occurs following standard vertebroplasty and…
- Conditions
- Cancer, Spinal Disease, Vertebral Compression Fractures
- Trial name
- NCT00819832
- Testing
- Kyphoplasty, Vertebroplasty, Cavity SpineWand
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- M.D. Anderson Cancer Center
Leukemia, Lymphoma
Donor Natural Killer Cell Infusion, Rituximab, Aldesleukin, and Chemotherapy in Treating Patients With Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia
RATIONALE: Aldesleukin may stimulate natural killer cells to kill cancer cells. Treating natural killer cells with aldesleukin in the laboratory may help the natural killer cells kill more cancer cells when they are put back in…
- Trial name
- NCT00625729
- Testing
- aldesleukin, allogeneic natural killer cells, rituximab
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Cardiooncology, Myeloma
Vascular Functions in Myeloma Patients During Anti-tumor Therapy
Treatment options for multiple myeloma have increased significantly over the last years with the approval of immunomodulatory drugs (IMiDs) and proteasome inhibitors (PIs).
- Conditions
- Cardiooncology, Myeloma, Endothelial Dysfunction
- Trial name
- NCT03776331
- Testing
- Flow mediated dilation
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- University Hospital, Essen